Search for a trial

A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma.

Part I: Evaluate the safety and tolerability of selinexor at 3 different dose levels in combination with bortezomib/dexamethasone & determine recommended dose level (RDL) of selinexor for Part IIPart II: Evaluate the efficacy of the…

A phase II study of Vorinostat in patients with Polycythaemia Vera and Essential Thrombocythaemia

1. To evaluate efficacy of vorinostat in the treatment of patients with polycythaemia vera (PV) and essential thrombocythaemia (ET) 2. To evaluate if vorinostat as monotherapy of patients with PV and ET is followed by a decline in clonal…

Intra-marrow transplantation of Mesenchymal Stromal Cells to treat MyeloDysplastic Syndromes: A feasibility study

This proposed study has three main objectives:1. To determine the feasibility of intra-marrow transplantation (IMT) of MSCs in lower risk MDS patients (a Phase I/II study):Although we have experience with application of (unrelated) MSCs and intra-…

A Phase Ib/II, open-label, multi-center, dose-finding study to assess the safety and efficacy of the oral combination of LDE225 and INC424 (Ruxolitinib) in patients with myelofibrosis

To establish the MTD and/or recommended phase II dose of the coadministration of LDE225 and INC424 in patients with MF, who have not previously received therapy with a JAK inhibitor

Generation of Dendritic cells from patients with breast cancer, multiple myeloma or ovarian cancer

To study (in vitro) if dendritic cells can be cultured with cells obtained from peripheral blood of patients with either m. myeloma, ovarian cancer or breast cancer. Thusfar we worked with cells from healthy volunteers. Before performing clinical…

An Open-label, Randomized Study of Subcutaneous and Intravenous VELCADE in Subjects With Previously Treated Multiple Myeloma

The primary objective is to compare the overall response rate ORR(CR+PR), after 4 cycles, of subcutaneously (SC) administered VELCADE tointravenously (IV) administered VELCADE in patients with previouslytreated multiple myeloma.The secondary…

Open-Label, Multi-Center, Phase 2 Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) in Subjects with Previously Treated Peripheral T-cell Lymphoma (PTCL)

The primary objective of this study will be:* To determine the overall response rate of KW-0761 for the treatment of patients with relapsed or refractoryPTCL;The secondary objectives of this study will be:* To determine the duration of response,…

Phase II single arm open pilot study to demonstrate the efficacy of midostaurin in symptom improvement and decrease of mast cell burden in patients with indolent or smoldering systemic mastocytosis

Primary: To study the efficacy and tolerability of Midostaurin in patients with indolent or smoldering systemic mastocytosis on mediator symptom reduction.Secondary: 1) To study whether Midostaurin can reduce mast cell infiltration and 2) to assess…

An open label extension study to evaluate the safety of long term dosing of AMG 531 in trombocytopenic subjects with myelodysplastic syndromes (MDS).

To provide long-term safety data for the use of AMG 531 in thrombocytopenic subjects with IPSS low or intermediate-1 risk MDS.

A phase I clinical trial to study the safety of treatment with Tipifarnib (ZARNESTRA) combined with Bortezomib (VELCADE) in patients with myelodysplastic syndrome (MDS)

To assess the safety of treatment with escalating dosages of VELCADE in combination with ZARNESTRA in subjects with Intermediate-2 or high risk MDS according to the IPSS classification.

An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

To evaluate safety and tolerability of AMG 531 in patients with low or intermediary-1 risk MDS and thrombocytopenia and to evaluate thrombocyte response at AMG 531 in these patients.

Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in previously untreated Patients with Waldenstrom*s Macroglobulinemia: A multicenter Trial of the European Myeloma Network

The primary objective of this study is:To determine the response rate [the combined complete response (CR) + partial response (PR) + minimal response (MR)] following treatment with BDR in patients with previously untreated WM.Secondary objectives…

A phase II, multicentre study of oral LBH589 in patients with accelerated phase or blast phase (blast crisis) chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors

Primary1. To assess the hematologic response and return to chronic phase rate in patients with accelerate phase or blasts crisis whose diseae is resistant following treatment with at lest two BCR-ABL tyrosine kinase inhibitors when treated with…

Infusion of mesenchymal stem cells as treatment for steroid resistant grade II to IV acute GVHD or poor graft function: a multicenter phase II study

This is a mulricenter phase II study examining the feasability and efficacy of this approach. Subjects will receive by intraveneus infusion a dose of MSC (aiming for 2 x 106/kg or highest avialable dose)

A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMML

Primary ObjectivesThe current study aims to establish the recommended dose, safety and preliminary efficacy of azacitidine administered IV or SC in children with relapsed/refractory MDS or JMML, in 2 different subgroups (strata) of patients.…

In vitro Screening of drug candidates against cancer and autoimmune diseases for effects on human blood cells

Primary Objective: Test the capacity of drug candidates to specifically inhibit the signalling pathways they target in human blood cells in vitro in the setting of human whole blood.Secondary Objective(s): Test whether drug candidates exert…

A phase 1 and phase 2 study of daratumumab in combination with all-trans retinoic acid in relapsed/refractory multiple myeloma

Evaluation of the effect of daratumumab in combination with ATRA in patients with relapsed/refractory multiple myeloma

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Primary Objectives:* Identify the maximum tolerated dose (MTD) of oprozomib formulations in combination with pomalidomide and dexamethasone (OPomd) in subjects with relapsed or refractory multiple myeloma* Evaluate the safety and tolerability of the…

A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies

Primary: Part 1: Safety and tolerability. Determine the MTD and/or RP2D of MAK683.Part 2: Anti-tumor activity of MAK683.Secondary: Part 1: Anti-tumor activity. Pharmacodynamics (PD). Pharmacokinetics (PK).Part 2: Safety and tolerability. PK, PD.

A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

Primary objective: To evaluate the efficacy of JNJ-68284528 (Phase 2)Secondary objectives:# To characterize the safety of JNJ-68284528 (Phase 2)# To characterize the pharmacokinetics and pharmacodynamics of JNJ-68284528# To assess the immunogenicity…